A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIIb Study to Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin and Sulfonylurea in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Combination of Metformin and Sulfonylurea.
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Saxagliptin (Primary) ; Metformin; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SaxaTOT
- 12 Jun 2012 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met according to results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
- 12 Jun 2012 Results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
- 06 Jun 2012 Actual patient number changed from 383 yo 257 as reported by ClinicalTrials.gov.